Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease

Background Recent examination of the STEADY‐PD III isradipine clinical trial data concluded that early‐stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end of the trial. These findings suggest that greater exposure to isradipine might slow disease progression. Objectives To test this hypothesis, the data...